Duality Biotherapeutics' Key Product DB-1310 Receives U.S. FDA Fast Track Designation for Advanced Lung Cancer Treatment

Reuters07-22

Duality Biotherapeutics' Key Product DB-1310 Receives U.S. FDA <a href="https://laohu8.com/S/FTRK">Fast Track</a> Designation for Advanced Lung <a href="https://laohu8.com/S/CTHZ">Cancer Treatment</a>

Duality Biotherapeutics Inc., a prominent player in the global ADC landscape, has announced that its key product, DB-1310, has been granted Fast Track Designation by the U.S. Food and Drug Administration (FDA). This designation is intended to expedite the development and review process for DB-1310, an antibody-drug conjugate targeting human epidermal growth factor receptor 3 (HER3). The drug is being developed for the treatment of adult patients with advanced, unresectable or metastatic non-squamous non-small cell lung cancer (nsqNSCLC) with specific genetic mutations and disease progression after prior therapies. The encouraging efficacy and manageable safety of DB-1310 were demonstrated in clinical trials, marking a significant step forward for Duality Biotherapeutics in bringing innovative cancer treatments to market.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Duality Biotherapeutics Inc. published the original content used to generate this news brief on July 22, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2553640410?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-22 06:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2553640410","market":"nz","top_or_hot":-1,"title":"Duality Biotherapeutics' Key Product DB-1310 Receives U.S. FDA Fast Track Designation for Advanced Lung Cancer Treatment","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Duality Biotherapeutics' Key Product DB-1310 Receives U.S. FDA <a href=\"https://laohu8.com/S/FTRK\">Fast Track</a> Designation for Advanced Lung <a href=\"https://laohu8.com/S/CTHZ\">Cancer Treatment</a>\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Duality Biotherapeutics Inc., a prominent player in the global ADC landscape, has announced that its key product, DB-1310, has been granted Fast Track Designation by the U.S. Food and Drug Administration (FDA). This designation is intended to expedite the development and review process for DB-1310, an antibody-drug conjugate targeting human epidermal growth factor receptor 3 (HER3). The drug is being developed for the treatment of adult patients with advanced, unresectable or metastatic non-squamous non-small cell lung cancer (nsqNSCLC) with specific genetic mutations and disease progression after prior therapies. The encouraging efficacy and manageable safety of DB-1310 were demonstrated in clinical trials, marking a significant step forward for Duality Biotherapeutics in bringing innovative cancer treatments to market.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Duality Biotherapeutics Inc. published the original content used to generate this news brief on July 22, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Duality Biotherapeutics' Key Product DB-1310 Receives U.S. FDA Fast Track Designation for Advanced Lung Cancer Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDuality Biotherapeutics' Key Product DB-1310 Receives U.S. FDA Fast Track Designation for Advanced Lung Cancer Treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-07-22 06:25</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Duality Biotherapeutics' Key Product DB-1310 Receives U.S. FDA <a href=\"https://laohu8.com/S/FTRK\">Fast Track</a> Designation for Advanced Lung <a href=\"https://laohu8.com/S/CTHZ\">Cancer Treatment</a>\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Duality Biotherapeutics Inc., a prominent player in the global ADC landscape, has announced that its key product, DB-1310, has been granted Fast Track Designation by the U.S. Food and Drug Administration (FDA). This designation is intended to expedite the development and review process for DB-1310, an antibody-drug conjugate targeting human epidermal growth factor receptor 3 (HER3). The drug is being developed for the treatment of adult patients with advanced, unresectable or metastatic non-squamous non-small cell lung cancer (nsqNSCLC) with specific genetic mutations and disease progression after prior therapies. The encouraging efficacy and manageable safety of DB-1310 were demonstrated in clinical trials, marking a significant step forward for Duality Biotherapeutics in bringing innovative cancer treatments to market.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Duality Biotherapeutics Inc. published the original content used to generate this news brief on July 22, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09606","symbol_name":"映恩生物-B","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250721:nNDL1rxbKY:1","article_id":"2553640410","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2553640410","pubTimestamp":1753136706,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Duality Biotherapeutics Inc., a prominent player in the global ADC landscape, has announced that its key product, DB-1310, has been granted Fast Track Designation by the U.S. Food and Drug Administration . This designation is intended to expedite the development and review process for DB-1310, an antibody-drug conjugate targeting human epidermal growth factor receptor 3 . The drug is being developed for the treatment of adult patients with advanced, unresectable or metastatic non-squamous non-small cell lung cancer  with specific genetic mutations and disease progression after prior therapies. The encouraging efficacy and manageable safety of DB-1310 were demonstrated in clinical trials, marking a significant step forward for Duality Biotherapeutics in bringing innovative cancer treatments to market.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated co","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09606":"映恩生物-B","BK1161":"生物科技"},"translate_title":"Duality Biotherapeutics关键产品DB-1310获美国FDA晚期肺癌治疗快速通道认定","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09606":0.9},"content_text":"Duality Biotherapeutics' Key Product DB-1310 Receives U.S. FDA Fast Track Designation for Advanced Lung Cancer Treatment\n\n\n        Duality Biotherapeutics Inc., a prominent player in the global ADC landscape, has announced that its key product, DB-1310, has been granted Fast Track Designation by the U.S. Food and Drug Administration (FDA). This designation is intended to expedite the development and review process for DB-1310, an antibody-drug conjugate targeting human epidermal growth factor receptor 3 (HER3). The drug is being developed for the treatment of adult patients with advanced, unresectable or metastatic non-squamous non-small cell lung cancer (nsqNSCLC) with specific genetic mutations and disease progression after prior therapies. The encouraging efficacy and manageable safety of DB-1310 were demonstrated in clinical trials, marking a significant step forward for Duality Biotherapeutics in bringing innovative cancer treatments to market.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Duality Biotherapeutics Inc. published the original content used to generate this news brief on July 22, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2553640410","isCrawlerRequest":true}